Schedule-dependent interactions between pemetrexed and cisplatin in human carcinoma cell lines in vitro

Oncology Research

Volumn 16, Issue 2, 2006, Pages 85-95

  Kano, Yasuhiko ^a   Akutsu, Miyuki ^a   Tsunoda, Saburo ^a   Izumi, Tohru ^a   Kobayashi, Hiroyuki ^a   Inoue, Koichi ^a   Mori, Kiyoshi ^a   Fujii, Hirofumi ^a   Mano, Hiroyuki ^b   Odgerel, Tsogbadrakh ^b   Furukawa, Yusuke ^b  

^a TOCHIGI CANCER CENTER   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Antagonism; Cisplatin; Isobologram; Pemetrexed; Synergism

Indexed keywords

CISPLATIN; PEMETREXED;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CARCINOMA CELL; CELL CYCLE; COLON CANCER; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG ANTAGONISM; DRUG DOSE REGIMEN; DRUG EXPOSURE; DRUG MECHANISM; DRUG POTENTIATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; INCUBATION TIME; LUNG CANCER; OVARY CANCER; PRIORITY JOURNAL;

EID: 33745727666     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: 10.3727/000000006783981215     Document Type: Article

References (33)

1. Taylor, E. C.; Kuhnt, D.; Shih, C.; Rinzel, S. M.; Grindey, G. B.; Barredo, J.; Jannatipour, M.; Moran, R. G. A dideazatetrahydrofolate analogue lacking a chiral center at C-6 N-[4-[2-(2-amino-34-dihydro-4-oxo-7H-pyrrolo[23- d]pyrimidin-5- yl)ethyl]benzoyl]-L-glutamic acid is an inhibitor of thymidylate synthase. J. Med. Chem. 35:4450-4454; 1992.
2. Habeck, L. L.; Mendelsohn, L. G.; Shih, C.; Taylor, E. C.; Colman, P. D.; Gossett, L. S.; Leitner, T. A.; Schultz, R. M.; Andis, S. L.; Moran, R. G. Substrate specificity of mammalian folypolyglutamate synthetase for 510-dideazatetrahydrofolate analogs. Mol. Pharmacol. 48: 326-333; 1995.
3. Shih, C.; Habeck, L. L.; Mendelsohn, L. G.; Chen, V. J.; Schultz, R. M. Multiple folate enzyme inhibition: Mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA). Adv. Enzyme Regul. 38:135-152; 1998.
4. Shih, C.; Thornton, D. E. Preclinical pharmacology studies and the clinical development of a novelmultitargeted antifolate MTA (LY231514) In: Jackman, A. L., ed. Anticancer drug development guide: Antifolate drugs in cancer therapy. Totowa, NJ: Humana Press; 1998:183-201.
5. McDonald, A. C.; Vasey, P. A.; Adams, L.; Walling, J.; Woodworth, J. R.; Abrahams, T.; McCarthy, S.; Bailey, N. P.; Siddiqui, N.; Lind, M. J.; Calvert, A. H.; Twelves, C. J.; Cassidy, J.; Kaye, S. B. A phase I and pharmacokinetic study of LY231514 the multitargeted antifolate. Clin. Cancer Res. 4:605-610; 1998.
6. Rinaldi, D. A. Overview of phase I trials of multitargeted antifolate (MTA LY231514). Semin. Oncol. 26(Suppl. 6): 82-88; 1999.
7. Rusthoven, J. J.; Eisenhauer, E.; Butts, C.; Gregg, R.; Dancey, J.; Fisher, B.; Iglesias, J. Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: A phase II study. National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 17:1194-1199; 1999.
8. John, W.; Picus, J.; Blanke, C. D.; Clark, J. W.; Schulman, L. N.; Rowinsky, E. K.; Thornton, D. E.; Loehrer, P. J. Activity of multitargeted antifolate (pemetrexed disodium LY231514) in patients with advanced colorectal carcinoma: Results from a phase II study. Cancer 88:1807-1813; 2000.
9. Hanauske, A. R.; Chen, V.; Paoletti, P.; Niyikiza, C. Pemetrexed disodium: A novel antifolate clinically active against multiple solid tumors. Oncologist 6:363-373; 2001.
10. Pivot, X.; Raymond, E.; Laguerre, B.; Degardin, M.; Cals, L.; Armand, J. P.; Lefebvre, J. L.; Gedouin, D.; Ripoche, V.; Kayitalire, L.; Niyikiza, C.; Johnson, R.; Latz, J.; Schneider, M. Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck. Br. J. Cancer 85:649-655; 2001.
11. Shepherd, F. A. Pemetrexed in the treatment of non-small cell lung cancer. Semin. Oncol. 29(Suppl. 18):43-48; 2002.
12. Calvert, H. Pemetrexed (Alimta): A promising new agent for the treatment of breast cancer. Semin. Oncol. 30 (Suppl. 3):2-5; 2003.
13. Scagliotti, G. V.; Shin, D. M.; Kindler, H. L.; Scagliotti, G. V.; Shin, D. M.; Kindler, H. L.; Vasconcelles, M. J.; Keppler, U.; Manegold, C.; Burris, H.; Gatzemeier, U.; Blatter, J.; Symanowski, J. T.; Rusthoven, J. J. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant therapy in malignant pleural mesothelioma. J. Clin. Oncol. 21:1556-1561; 2003.
14. Hanna, N.; Shepherd, F. A.; Fossella, F. V.; Pereira, J. R.; De Marinis, F.; von Pawel, J.; Gatzemeier, U.; Tsao, T. C.; Pless, M.; Muller, T.; Lim, H. L.; Desch, C.; Szondy, K.; Gervais, R.; Shaharyar; Manegold, C.; Paul, S.; Paoletti, P.; Einhorn, L.; Bunn, Jr., P. A. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J. Clin. Oncol. 22:1589-1597; 2004.
15. Thodtmann, R.; Depenbrock, H.; Dumez, H.; Blatter, J.; Johnson, R. D.; van Oosterom, A.; Hanauske, A. R. Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin. J. Clin. Oncol. 17:3009-3016; 1999.
16. Manegold, C.; Gatzemeier, U.; von Pawel, J.; Pirker, R.; Malayeri, R.; Blatter, J.; Krejcy, K. Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514 pemetrexed disodium ALIMTA) and cisplatin: A multicenter phase II trial. Ann. Oncol. 11:435-440; 2000.
17. Shepherd, F. A.; Dancey, J.; Arnold, A.; Neville, A.; Rusthoven, J.; Johnson, R. D.; Fisher, B.; Eisenhauer, E. Phase II study of pemetrexed disodium a multitargeted antifolate and cisplatin as first-line therapy in patients with advanced non small cell lung carcinoma: A study of the National Cancer Institute of Canada Clinical Trials Group. Cancer 92:595-600; 2001.
18. Vogelzang, N. J.; Rusthoven, J. J.; Symanowski, J.; Denham, C.; Kaukel, E.; Ruffle, P.; Gatzemeier, U.; Boyer, M.; Emri, S.; Manegold, C.; Niyikiza, C.; Paoletti, P. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol. 21:2636-2644; 2003.
19. Scagliotti, G. V.; Kortsik, C.; Dark, G. G.; Price, A.; Manegold, C.; Rosell, R.; O'Brien, M.; Peterson, P. M.; Castellano, D.; Selvaggi, G.; Novello, S.; Blatter, J.; Kayitalire, L.; Crino, L.; Paz-Ares, L.; Go, R. S. Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: A multicenter, randomized, phase II trial. Clin. Cancer Res. 11(2 Pt. 1):690-696; 2005.
20. Adjei, A. A. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J. Clin. Oncol. 17:409-422; 1999.
21. Jackel, M.; Kopf-Maier, P. Influence of cisplatin on cell-cycle progression in xenografted human head and neck carcinomas. Cancer Chemother. Pharmacol. 27:464-471; 1991.
22. Tonkinson, J. L.; Marder, P.; Andis, S. L.; Schultz, R. M.; Gossett, L. S.; Shih, C.; Mendelsohn, L. G. Cell cycle effects of antifolate antimetabolites: Implications for cytotoxicity and cytostasis. Cancer Chemother. Pharmacol. 39: 521-531; 1997.
23. Tonkinson, J. L.; Worzalla, J. F.; Teng, C. H.; Mendelsohn, L. G. Cell cycle modulation by a multitargeted antifolate, LY231514, increases the cytotoxicity and antitumor activity of gemcitabine in HT29 colon carcinoma. Cancer Res. 59:3671-3676; 1999.
24. Schultz, R. M.; Dempsey, J. A. Sequence dependence of Alimta (LY231514, MTA) combined with doxorubicin in ZR-75-1 human breast carcinoma cells. Anticancer Res. 21:3209-3214; 2001.
25. Kano, Y.; Akutsu, M.; Tsunoda, S.; Izumi, T.; Mori, K.; Fujii, H.; Yazawa, Y.; Mano, H.; Furukawa, Y. Schedule-dependent synergism and antagonism between pemetrexed and paclitaxel in human carcinoma cell lines in vitro. Cancer Chemother. Pharmacol. 54:505-513; 2004.
26. Teicher, B. A.; Alvarez, E.; Liu, P.; Lu, K.; Menon, K.; Dempsey, J.; Schultz, R. M. MTA (LY231514) in combination treatment regimens using human tumor xenografts and the EMT-6 murine mammary carcinoma. Semin. Oncol. 28:55-62; 1999.
27. Teicher, B. A.; Chen, V.; Shih, C.; Menon, K.; Forler, P. A.; Phares, V. G.; Amsrud, T. Treatment regimens including the multitargeted antifolate LY231514 in human tumor xenografts. Clin. Cancer Res. 6:1016-1023; 2000.
28. Kano, Y.; Sakamoto, S.; Kasahara, T.; Akutsu, M.; Inoue, Y.; Miura, Y. In vitro effects of amsacrine in combination with other anticancer agents. Leukemia Res. 15:1059-1064; 1991.
29. Steel, G. G.; Peckham, M. J. Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int. J. Radiat. Oncol. Biol. Phys. 5:85-91; 1979.
30. Kano, Y.; Ohnuma, T.; Okano, T.; Holland, J. F. Effects of vincristine in combination with methotrexate and other antitumor agents in human acute lymphoblastic leukemia cells in culture. Cancer Res. 48:351-356; 1988.
31. Kano, Y.; Akutsu, M.; Tsunoda, S.; Mano, H.; Sato, Y.; Honma, Y.; Furukawa, Y. In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood 97:1999-2007; 2001.
32. Kano, Y.; Akutsu, M.; Tsunoda, S.; Suzuki, K.; Adachi, K. In vitro schedule-dependent interaction between paclitaxel and SN-38 (the active metabolite of irinotecan) in human carcinoma cell lines. Cancer Chemother. Pharmacol. 42:91-98; 1998.
33. Furukawa, Y.; Iwase, S.; Kikuchi, J.; Nakamura, M.; Terui, Y.; Yamada, H.; Kano, Y.; Matsuda, M. Phosphorylation of bcl-2 protein by cdc2 Kinase during G2/M phases and its role in cell cycle regulation. J. Biol. Chem. 275:21661-21667; 2000.